The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Becton, Dickinson and Company (NYSE:BDX ) Barclays 27th Annual Global Healthcare Conference March 11, 2025 8:30 AM ET Company Participants Tom Polen - Chairman, Chief Executive Officer and President Chris DelOrefice - Executive Vice President and Chief Financial Officer Conference Call Participants Unidentified Analyst [Call Starts Abruptly] Everyone for joining us today. We are so pleased to have with us again this year the team from Becton, Dickinson, Tom Polen, Chairman, Chief Executive Officer and Chris DelOrefice, EVP and Chief Financial Officer.
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
While the top- and bottom-line numbers for Becton Dickinson (BDX) give a sense of how the business performed in the quarter ended December 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Becton Dickinson (BDX) came out with quarterly earnings of $3.43 per share, beating the Zacks Consensus Estimate of $2.98 per share. This compares to earnings of $2.68 per share a year ago.
The continued solid uptake of BD's products is expected to have driven fiscal first-quarter revenues despite transitory market dynamics.
Besides Wall Street's top -and-bottom-line estimates for Becton Dickinson (BDX), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended December 2024.
Becton Dickinson (BDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
BD and Biosero collaborate to integrate robotic automation with flow cytometry technology, aiming to accelerate drug discovery.